Posted on 12/9/16
Better Buy: Johnson & Johnson vs. Pfizer Inc.
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) have several things in common. They're two of the biggest drugmakers in the world. The stocks are popular among . . .
Posted on 12/9/16
Oscar Center Opens in Downtown Brooklyn
Health insurance startup Oscar today announced the opening of the Oscar Center in Downtown Brooklyn, New York, which provides health and wellness services and access to . . .
Posted on 12/8/16
Ohr Pharmaceutical Prices $7.75M Public Offering of Common Stock
NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it has priced a registered . . .
Posted on 12/8/16
Why You Should (and Shouldn't) Buy Celldex Therapeutics, Inc.
President-elect Trump's pledge to ease corporate taxes on repatriated capital stashed overseas has the market buzzing over Celldex Therapeutics (NASDAQ:CLDX) and other small-cap biotechs.IMAGE SOURCE: GETTY . . .
Posted on 12/8/16
Why Celldex Rallied 22% In November
IMAGE SOURCE: GETTY IMAGES.What happenedAfter announcing the acquisition of the privately held Kolltan and reporting third-quarter financials, shares in Celldex Therapeutics (NASDAQ:CLDX) jumped 22% last month, . . .
Posted on 12/8/16
Better Buy: Amgen Inc. vs. Pfizer
IMAGE SOURCE: GETTY IMAGES.Over the past five years, Amgen (NASDAQ:AMGN) investors have enjoyed a market-thumping 166.1% gain. During the same period, Pfizer (NYSE:PFE) shares rose just . . .
Posted on 12/8/16
Is Pfizer's New PD-L1 Drug a Game-Changer?
The Food and Drug Administration has agreed to review Pfizer Inc.'s (NYSE:PFE) PD-L1 checkpoint inhibitor, avelumab, under an accelerated approval pathway. If it's given the go-ahead, . . .
Posted on 12/8/16
Better Buy: Johnson & Johnson vs. Eli Lilly
Just ahead of the Thanksgiving holiday, Eli Lilly (NYSE:LLY) announced the third late-stage clinical failure for its Alzheimer's disease candidate. The stock had given up some . . .
Posted on 12/8/16
Simpson Healthcare Executives Honored as 2016 eHealthcare Leadership Awards Winner at the 20th Annual Healthcare Internet Conference
Simpson Healthcare Executives, a global leader in biopharmaceutical consulting, announced that they received a highly competitive Award of Distinction from the eHealthcare Leadership Awards program for . . .
Posted on 12/7/16
Zoetis Announces Authorization of $1.5 Billion Share Repurchase Program
ARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has authorized a $1.5 billion multi-year share repurchase program as part of its . . .
Posted on 12/6/16
Read This Before You Buy Biotech Stocks
Plenty of growth investors flock to biotech stocks because the industry can provide eye-popping gains. For example, shares of Tesaro (NASDAQ:TSRO) more than doubled after the . . .
Posted on 12/6/16
The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November
IMAGE SOURCE: GETTY IMAGES.What happenedShares of Achillion Pharmaceuticals (NASDAQ:ACHN), a developmental-stage developer of small-molecule drugs to treat autoimmune diseases and infectious diseases such as hepatitis C, . . .
Posted on 12/6/16
Here's Why Regeneron Pharmaceuticals, Inc. Jumped 9.4% in November
IMAGE SOURCE: GETTY IMAGES.What happenedShares of biotech giant Regeneron Pharmaceuticals (NASDAQ:REGN) rose more than 9% in November, according to data from S&P Global Market Intelligence. That . . .
Posted on 12/5/16
Cigna Earns Top Marks in 2017 Corporate Equality Index for 5th Consecutive Year
BLOOMFIELD, Conn.--(BUSINESS WIRE)--Cigna (NYSE: CI), a health service company, proudly announced that it received a perfect score of 100 on the 2017 Corporate Equality Index (CEI), . . .
Posted on 12/5/16
Regeneron's CEO Blasts Peers on Innovation
Regeneron Pharmaceuticals (NASDAQ:REGN) CEO Leonard Schleifer's frustration boiled over at Forbes Healthcare Summit in New York this week. The CEO called out his peers for driving . . .
Posted on 12/5/16
Forget Pfizer: Here Are 3 Better Dividend Stocks
When people think dividend stocks, Pfizer (NYSE:PFE) is sure to be high on the list. After all, the massive pharma stock pays out 3.75% annually, solidly . . .
Posted on 12/5/16
Why Bristol-Myers Squibb Co. Stock Surged in November
IMAGE SOURCE: GETTY IMAGES.What happenedAccording to data from S&P Global Market Intelligence, Bristol-Myers Squibb's (NYSE:BMY) stock climbed higher by more than 11% last month. This double-digit . . .
Posted on 12/5/16
Does Pfizer Pass Warren Buffett’s Test?
Warren Buffett has a long and storied history of using Berkshire Hathaway's financial might to make earth-shattering acquisitions. Over the years he has spent tens of . . .
Posted on 12/5/16
This Trump Appointment Likely Spells Imminent Doom for Obamacare
IMAGE SOURCE: GETTY IMAGES.The Affordable Care Act as we know it could be on its last legs.The ACA, which is more commonly known as Obamacare, transformed . . .
Posted on 12/4/16
Retro Fitness Expands Florida Footprint through Franchising
COLTS NECK, N.J.--(BUSINESS WIRE)--Retro Fitness, a fast-growing, national low-cost, high-value fitness franchise, is targeting the Sunshine State for significant expansion. With six franchise locations already open . . .
Posted on 12/1/16
Agile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding
PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company announced today that it has received net proceeds . . .
Posted on 12/1/16
What's Pfizer's Excuse for Not Buying Exelixis?
Exelixis Inc. (NASDAQ:EXEL) reported in October that its kidney cancer drug Cabometyx outperformed Pfizer Inc.'s (NYSE:PFE) top-selling Sutent in first-line advanced kidney cancer patients. Exelixis' management . . .
Posted on 11/30/16
Merck Boosts Dividend 2% And Has Several Key Growth Drivers
Merck (NYSE:MRK) recently increased its dividend by 2%. Its overall yield is above that of the S&P 500 Index, at 3.02%. The firm has paid a . . .
Posted on 11/30/16
J&J - Approaching Value Territory, But I Am Not Waiting
Johnson & Johnson (NYSE:JNJ) is approaching value territory, but I am not waiting. Given my investment horizon, I don't try to catch the last 5% downside . . .
Posted on 11/29/16
Celgene Stock Split: Is the Biotech Ready to Split Again?
The biotechnology industry has been a huge growth engine for the stock market in recent years, and Celgene (NASDAQ:CELG) stands as one of the biggest players . . .
New York
